Cryoport (CYRX) Expected to Announce Earnings on Tuesday

Cryoport (NASDAQ:CYRX) is expected to post its quarterly earnings results after the market closes on Tuesday, March 4th. Analysts expect Cryoport to post earnings of ($0.33) per share and revenue of $58.71 million for the quarter. Individual that are interested in participating in the company’s earnings conference call can do so using this link.

Cryoport Trading Up 1.8 %

Shares of NASDAQ CYRX opened at $6.33 on Tuesday. The stock has a market capitalization of $312.90 million, a P/E ratio of -1.87 and a beta of 1.59. The business’s 50 day moving average is $7.62 and its two-hundred day moving average is $7.75. Cryoport has a 1-year low of $5.32 and a 1-year high of $20.10. The company has a debt-to-equity ratio of 0.48, a current ratio of 5.70 and a quick ratio of 5.32.

Insiders Place Their Bets

In other Cryoport news, Director Ramkumar Mandalam sold 7,369 shares of the company’s stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $7.46, for a total transaction of $54,972.74. Following the completion of the sale, the director now owns 59,497 shares in the company, valued at $443,847.62. This represents a 11.02 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 10.10% of the stock is owned by company insiders.

Analyst Ratings Changes

A number of research analysts have recently commented on CYRX shares. Guggenheim started coverage on Cryoport in a research note on Thursday, December 19th. They set a “buy” rating and a $11.00 target price on the stock. Needham & Company LLC reaffirmed a “buy” rating and set a $11.00 target price on shares of Cryoport in a research note on Friday, January 17th. Finally, Roth Mkm cut their target price on Cryoport from $18.00 to $15.00 and set a “buy” rating on the stock in a research note on Friday, November 8th. Three equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat.com, Cryoport has a consensus rating of “Moderate Buy” and an average target price of $12.29.

Cryoport Company Profile

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.